Study of disease progression in people with MPS IIIC
Part of Genetic & congenital, Hormones & metabolism, Skin clinical trials.
This study follows people with MPS IIIC over time to learn more about how the disease progresses. It does not test a new treatment, but the information may help with future care and research.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 1 to 25 years old
- Have a confirmed diagnosis of MPS IIIC (Sanfilippo syndrome type C) through genetic and enzyme testing
- Have a caregiver who is willing to do home visits and assessments
- Need health insurance and a smartphone or tablet with internet
- Speak one of these languages as your first language: English, Spanish, French, German, or Portuguese
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with Sanfilippo syndrome type C to better understand how the disease changes over time. It does not appear to test a new medicine; instead, it collects health and development information that can help future treatments.
This study follows people with MPS, a rare genetic condition, to learn more about the disease over time. If you have a confirmed MPS diagnosis, you may be able to join.
This study follows people with MPS IIIA (Sanfilippo syndrome type A) who have received or plan to receive the gene therapy rebisufligene etisparvovec, to monitor their health and treatment effects over time.
This trial enrolls people with mucopolysaccharidosis type VII (MPS VII) to track their health over time. It may help your care team better understand how the condition behaves and how monitoring should be done.
This trial tests a gene-transfer treatment (delivered into the spinal fluid) for children with MPS IIIA, a rare genetic condition. It aims to improve or slow down brain and developmental changes caused by a missing enzyme.
This follow-up study looks at how a past gene therapy treatment (UX111) is affecting you over time. It mainly involves continued visits and safety checks, and it helps researchers understand long-term benefits and risks.
Hear when a new Sanfilippo Syndrome Type C trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.